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CONCLUSIONS: GMMs have the potential to increase understanding of treatment
effects and identify patients more likely to benefit from treatment. The ability of
baseline characteristics to predict responders/non-responders needs to be tested
prospectively.
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OCULAR DISCOMFORT, COMPLIANCE AND INTRA-OCULAR PRESSURE (IOP)
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OBJECTIVES: To investigate the associations between ocular discomfort, compli-
ance and efficacy of IOP lowering drugs. METHODS: This was a prospective obser-
vational survey. Centres were selected at random from the CEGEDIM list. Consec-
utive patients treated with an IOP lowering fixed combination drug (prostaglandin
analogues excluded) were included. IOP was collected at two visits (delay fixed by
the investigator). Self-reported compliance measured by validated questionnaires
(EDSQ, TSQM and TEO) and self-reported ocular discomfort (13 items with a focus
at instillation and during the day) based on a questionnaire developed according to
international patient reported outcome recommendations were collected at the
last visit. Patients were classified into 3 groups of compliance (good, minor and
major issues) using the TEO published algorithm. Comparisons between compli-
ance groups were made by ANOVA and chi-square tests. Adjustments were made
for confounding variable unbalances. RESULTS: 410 patients (66 years old, 237
females, 101 ocular hypertensions) were included. 32.9% reported good compli-
ance, 55.9% minor and 11.2% major compliance issues. Patients reporting either red
eyes (P0.02), stinging (P0.007), feeling of sand in the eyes (P0.0009), dry eye
(P0.02), or blurry vision (P0.002) were more likely to report compliance issues.
Patients in the good compliance group reported 3.2 ocular discomfort concerns, 4.5
in the minor and 5.2 in the major compliance issue group (P0.0002). The proba-
bilities to report no concern were 24.2%, 12.7% and 11.9% (P0.02), respectively. An
association between IOP control and compliance was reported in the group of
patients that did not have a change in treatment at the first visit: patients in the
good compliance group had an IOP decrease of 0.9 mmHg, 0.3 mmHg in the minor
and a 0.2 mmHg increase in the major compliance issue group. CONCLUSIONS:
Ocular discomfort issues reported by patients might impact compliance leading to
poor IOP control.
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OBJECTIVES: To determine the prevalence, demographics and treatment charac-
teristics of patients with visual impairment (VI) due to diabetic macular edema
(DME) in a real-world Canadian setting. METHODS: Records from a longitudinal
population-based database of more than 170,000 patients in 53 family practice
clinics in southwestern Ontario, Canada were analyzed between January 1, 2008 to
December 31, 2009. Patient records were limited to those aged 18 years of age and
older. These records contained chart-abstracted information such as visit diagno-
sis, medications and consultation notes. Initial extractions of control, diabetic and
DME patients with VI, defined as best corrected visual acuity20/40 in the DME eye,
were accomplished utilizing International Classification of Disease codes (ICD9/
ICD10); reviewing patient charts for text entries of symptoms that supported a
diagnosis of diabetes and DME and concomitant comorbidity; and reviewing pa-
tient treatment records unique to DME with VI including consultation notes and
hospital discharge summaries. Demographic characteristics, comorbidities, and
treatment were reported. RESULTS: 8368 patients with type 1 or 2 diabetes and a
control cohort of 76,077 patients were extracted for this analysis. Among diabetic
patients, prevalence of DME was 15.7%. Average duration of diabetes among pa-
tients with DME was 19 years. More patients with DME had hypertension (66%), or
vascular disease (28%) than the control cohort (p0.05). The prevalence of VI due to
DME was 2.56%. Mean age was 6417. In patients with VI due to DME, 53% had focal
and 47% had diffuse edema. For both focal and diffuse edema, the most common
treatment was laser monotherapy, used in 62% and 53% of cases, respectively.
CONCLUSIONS: : In a real-world setting, among patients with diabetes, we ob-
served the prevalence of VI due to DME at 2.56% . Laser monotherapy was the most
common treatment.
PSS3
INCIDENCE AND CHARACTERISTICS OF PATIENTS WITH MACULAR EDEMA
SECONDARY TO RETINAL VEIN OCCLUSION IN A REPRESENTATIVE CANADIAN
COHORT
Petrella RJ1, Blouin J2, Davies B2, Barbeau M2
1Lawson Health Research Institute, indivisual health outcomes inc, London, ON, Canada,
2Novartis Pharmaceuticals Canada Inc, Dorval, QC, Canada
OBJECTIVES: Retinal vein occlusion (RVO) has an abrupt onset and is an important
cause of visual morbidity. Macular edema (ME) is the most common cause of visual
impairment (VI) in patients with RVO. The Canadian incidence of VI due to ME
secondary to RVO is unknown. This study aimed to determine the annual incidence
and characteristics of patients with ME secondary to branch RVO (BRVO) and cen-
tral RVO (CRVO) in a real-world Canadian setting. METHODS: Records from a lon-
gitudinal population-based database of more than 170,000 patients in 53 family
practice clinics in southwestern Ontario, Canada were analyzed between January 1,
2008 and December 31, 2009. These records contained chart-abstracted informa-
tion such as visit diagnosis, medications and consultation notes. Initial extractions
of control cohort and RVO patients with ME and VI (defined as best corrected visual
acuity 20/40 in the RVO eye), were accomplished utilizing International Classifi-
cation of Disease codes (ICD9/ICD10); reviewing patient charts for text entries of
symptoms that supported a diagnosis of RVO and concomitant comorbidity; and
reviewing patient treatment records unique to RVO including consultation notes
and hospital discharge summaries. Demographic characteristics and comorbidi-
ties were reported. RESULTS: Seventy-three (53 with BRVO and 20 with CRVO) of
47,166 patients over 40 years (mean age 6117 years) with new diagnosis of RVO
and a control cohort of 76,077 patients were extracted for this analysis. The annual
incidence of VI due to ME secondary to BRVO and CRVO was 0.056% and 0.021%,
respectively. More RVO patients had hypertension (68 vs. 18%) or dyslipidemia (16
vs. 10%) than control cohort (p0.05). One-quarter of RVO patients had a history of
vascular disease, primarily MI and stroke. CONCLUSIONS: In a real-world setting,
the annual incidence of VI due to ME secondary to BRVO and CRVO was 0.056% and
0.021%, respectively. RVO is associated with several vascular comorbidities.
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OBJECTIVES: The presence of the preservative benzalkonium chloride (BAK) at
0.01% concentration in commercialized prostaglandin eye drops for glaucoma is
known to increase the risk of ocular surface disease (OSD), which worsens with the
extent of exposure to BAK. We aimed to estimate longer term clinical outcomes
with travoprost preserved with Polyquad® 0.001% instead of BAK. METHODS: A
Markov microsimulation model was developed (TreeAge) to assess the develop-
ment of OSD and disease progression (Mean Defect [MD], in db) over 10 years, in
patients initiating travoprost with Polyquad® followed by travoprost/beta-blocker
fixed combination vs. the same sequence using BAK-preserved drops. Initial pa-
tient’s characteristics came from distributions on age (normal), sex, OSD presence,
disease stage (uniform) and anticipated progression rates (triangular). The risk of
developing OSD in aging population was derived from a US incidence study, mul-
tiplied by independent risk factors (age, sex, duration and amount of BAK-contain-
ing drops received). Rates of disease progression (db/year) came from landmark
studies in OHT/glaucoma, multiplied by independent accelerating factors (disease
stage, treatment line, OSD severity, non-compliance). Compliance was expected by
experts to be 20% (absolute) better with Polyquad® vs. BAK-preserved drops.
RESULTS: Using 3000 trials (mean age 57 years, 57% female, 14% with initial OSD,
mean MD -4db), 47.6% [41.5-53.6%] of patients receiving in first and second line
BAK-preserved travoprost treatments are expected to have OSD at 10 years versus
31.7% [28.5-35.1%] with Polyquad®. In OHT/early glaucoma patients, the model
predicted the progression to advanced glaucoma (MD-12db) of 13.2% [12.0-14.4%]
with Polyquad® versus 18.1% [16.7-19.5%] with BAK. In patients diagnosed with
moderate glaucoma, 1.9% [1.4-2.4%] versus 5.6% [4.8-6.4%] progressed to blindness
(MD-24db) respectively. CONCLUSIONS: The model estimated that OSD inci-
dence was reduced by 33% and glaucoma disease progression was significantly less
frequent after 10 years of use of Polyquad® versus BAK-containing travoprost eye
drops.
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OBJECTIVES: The progression of glaucoma is measured by a Mean Defect (MD) of
the perimetry in decibels (db), from an early disease stage (6db loss), until mod-
erate (6-12db loss), advanced stages (12-24db loss) and eventually blindness (24db
loss). The rate of disease progression is highly variable between individuals and
hard to predict. The objective of this study was to analyze the change in MD of
glaucoma patients in a real-life setting in Germany. METHODS: We analyzed pa-
tient-level data from a German observational study in ocular hypertension (OHT)
and glaucoma, with retrospective collection of MD measures (db). Descriptive sta-
tistics were derived on the rate of disease progression (db loss/year, obtained by
dividing the change in MD by the duration of observation). The change in MD in
best eye between the time of first treatment until last MD measure was included in
a generalized linear regression, adjusting for age, sex, presence of cataract, time
since first treatment, initial MD and initial glaucoma stage (OHT, early/moderate or
advanced). RESULTS: MD data was available for 57 patients (53% female, mean age
67 /12 years). The mean (SD) time from first treatment until last MD measure
was 7.0 (3.7) years. The mean (SD) MD was -4.5db (4.7) at first treatment and -6.0db
(6.8) at last assessment (i.e. average rate of progression of -0.21db/year, all stages).
In 12 OHT patients, 50% had no MD worsening, while 50% lost on average -0.26db/
year. Based on the adjusted analysis, the initial diagnosis was significantly associ-
ated with the amount of db loss over time (early/moderate glaucoma -0.19db/year
/0.13, advanced -0.66db/year /0.22, p0.038). CONCLUSIONS: The rates of
disease progression measured over more than 7 years in glaucoma patients was
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